{"id":"https://openalex.org/W7225259668","doi":"https://doi.org/10.1111/ddg.70717","title":"Successful bimekizumab retreatment after secondary failure in multi\u2010biologic\u2010resistant psoriasis","display_name":"Successful bimekizumab retreatment after secondary failure in multi\u2010biologic\u2010resistant psoriasis","publication_year":2026,"publication_date":"2026-11-03","ids":{"openalex":"https://openalex.org/W7225259668","doi":"https://doi.org/10.1111/ddg.70717","pmid":"https://pubmed.ncbi.nlm.nih.gov/42978282"},"language":"en","primary_location":{"id":"doi:10.1111/ddg.70717","doi":"https://doi.org/10.1111/ddg.70717","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ddg.70717","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.70717","source":{"id":"https://openalex.org/S4210169996","display_name":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","issn_l":"1610-0379","issn":["1610-0379","1610-0387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.70717","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5115826034","display_name":"Nicole Kah Mun Yoong","orcid":"https://orcid.org/0009-0000-7110-4868","observed_orcids":["https://orcid.org/0009-0000-7110-4868"]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Nicole Kah Mun Yoong","raw_affiliation_strings":["Monash Health Clayton VIC 3168, Australia"],"raw_orcid":"https://orcid.org/0009-0000-7110-4868","affiliations":[{"raw_affiliation_string":"Monash Health Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I4210121067"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160574892","display_name":"Melinda Withington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Melinda Withington","raw_affiliation_strings":["Monash Health Clayton VIC 3168, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash Health Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I4210121067"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084117414","display_name":"Francis Yi Xing Lai","orcid":"https://orcid.org/0000-0003-3976-1432","observed_orcids":["https://orcid.org/0000-0003-3976-1432"]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]},{"id":"https://openalex.org/I4210165890","display_name":"Skin Health Institute","ror":"https://ror.org/05x56xv16","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210165890"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Francis Yi Xing Lai","raw_affiliation_strings":["Monash Health Clayton VIC 3168, Australia","Skin Health Institute Carlton VIC 3053, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash Health Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I4210121067"]},{"raw_affiliation_string":"Skin Health Institute Carlton VIC 3053, Australia","institution_ids":["https://openalex.org/I4210165890"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067138797","display_name":"Paul Curnow","orcid":"https://orcid.org/0000-0001-9889-0248","observed_orcids":["https://orcid.org/0000-0001-9889-0248"]},"institutions":[{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Paul Curnow","raw_affiliation_strings":["Monash Health Clayton VIC 3168, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Monash Health Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I4210121067"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5001658092","display_name":"Senhong Lee","orcid":"https://orcid.org/0000-0003-0246-0484","observed_orcids":["https://orcid.org/0000-0003-0246-0484"]},"institutions":[{"id":"https://openalex.org/I4210098920","display_name":"Eastern Health","ror":"https://ror.org/00vyyx863","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210098920"]},{"id":"https://openalex.org/I4210121067","display_name":"Monash Health","ror":"https://ror.org/02t1bej08","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210121067"]},{"id":"https://openalex.org/I4210165890","display_name":"Skin Health Institute","ror":"https://ror.org/05x56xv16","country_code":"AU","type":"nonprofit","lineage":["https://openalex.org/I4210165890"]},{"id":"https://openalex.org/I56590836","display_name":"Monash University","ror":"https://ror.org/02bfwt286","country_code":"AU","type":"education","lineage":["https://openalex.org/I56590836"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Senhong Lee","raw_affiliation_strings":["Eastern Health Box Hill VIC 3128, Australia","Monash Health Clayton VIC 3168, Australia","Monash University Clayton VIC 3168, Australia","Skin Health Institute Carlton VIC 3053, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eastern Health Box Hill VIC 3128, Australia","institution_ids":["https://openalex.org/I4210098920"]},{"raw_affiliation_string":"Monash Health Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I4210121067"]},{"raw_affiliation_string":"Monash University Clayton VIC 3168, Australia","institution_ids":["https://openalex.org/I56590836"]},{"raw_affiliation_string":"Skin Health Institute Carlton VIC 3053, Australia","institution_ids":["https://openalex.org/I4210165890"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5001658092"],"corresponding_institution_ids":["https://openalex.org/I4210098920","https://openalex.org/I4210121067","https://openalex.org/I4210165890","https://openalex.org/I56590836"],"apc_list":{"value":4480,"currency":"USD","value_usd":4480},"apc_paid":{"value":4480,"currency":"USD","value_usd":4480},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.79880919,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11092","display_name":"Spondyloarthritis Studies and Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9648000001907349},{"id":"https://openalex.org/C2777226972","wikidata":"https://www.wikidata.org/wiki/Q415343","display_name":"Etanercept","level":3,"score":0.7095999717712402},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.6919000148773193},{"id":"https://openalex.org/C2778975655","wikidata":"https://www.wikidata.org/wiki/Q420305","display_name":"Ustekinumab","level":4,"score":0.6725999712944031},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.66839998960495},{"id":"https://openalex.org/C2779745271","wikidata":"https://www.wikidata.org/wiki/Q13574436","display_name":"Ixekizumab","level":5,"score":0.6467999815940857},{"id":"https://openalex.org/C2779786854","wikidata":"https://www.wikidata.org/wiki/Q7444755","display_name":"Secukinumab","level":4,"score":0.613099992275238},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.5909000039100647},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.5906999707221985},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.5860999822616577},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.5791000127792358},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4058000147342682},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.37779998779296875},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.32030001282691956},{"id":"https://openalex.org/C2778496887","wikidata":"https://www.wikidata.org/wiki/Q341500","display_name":"Acitretin","level":3,"score":0.2955000102519989},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2896000146865845},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.2831000089645386},{"id":"https://openalex.org/C544821477","wikidata":"https://www.wikidata.org/wiki/Q718113","display_name":"Weight loss","level":3,"score":0.2815000116825104},{"id":"https://openalex.org/C2781228260","wikidata":"https://www.wikidata.org/wiki/Q415411","display_name":"Anakinra","level":3,"score":0.2777999937534332},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.27720001339912415},{"id":"https://openalex.org/C2781290027","wikidata":"https://www.wikidata.org/wiki/Q413879","display_name":"Golimumab","level":4,"score":0.27630001306533813},{"id":"https://openalex.org/C2777077863","wikidata":"https://www.wikidata.org/wiki/Q170990","display_name":"Arthritis","level":2,"score":0.274399995803833},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2736000120639801},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.27300000190734863},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.25429999828338623},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.2526000142097473}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1111/ddg.70717","doi":"https://doi.org/10.1111/ddg.70717","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ddg.70717","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.70717","source":{"id":"https://openalex.org/S4210169996","display_name":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","issn_l":"1610-0379","issn":["1610-0379","1610-0387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","raw_type":"journal-article"},{"id":"pmid:42978282","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42978282","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","raw_type":"Case Reports"}],"best_oa_location":{"id":"doi:10.1111/ddg.70717","doi":"https://doi.org/10.1111/ddg.70717","is_oa":true,"landing_page_url":"https://doi.org/10.1111/ddg.70717","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.70717","source":{"id":"https://openalex.org/S4210169996","display_name":"JDDG Journal der Deutschen Dermatologischen Gesellschaft","issn_l":"1610-0379","issn":["1610-0379","1610-0387"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","raw_type":"journal-article"},"sustainable_development_goals":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225259668.pdf","grobid_xml":"https://content.openalex.org/works/W7225259668.grobid-xml"},"referenced_works_count":5,"referenced_works":["https://openalex.org/W2767159479","https://openalex.org/W2895180416","https://openalex.org/W4413020660","https://openalex.org/W7142442843","https://openalex.org/W7161248974"],"related_works":[],"abstract_inverted_index":{"Dear":[0],"Editors,":[1],"A":[2],"22-year-old":[3],"male":[4],"with":[5,10,28,138,159,180,191,217,287,342,347,383,411,422,467],"longstanding":[6],"severe":[7,525],"plaque":[8,349],"psoriasis":[9,188],"baseline":[11],"Psoriasis":[12],"Area":[13],"and":[14,21,62,116,124,162,212,215,221,246,302,359,386,418,478,522,536,567,607,626],"Severity":[15],"Index":[16],"(PASI)":[17],"score":[18,227],"of":[19,24,50,141,154,197,250,259,300,319,353,368,402,407,488,553,569,584,622,644,654],"48":[20],"no":[22],"history":[23],"psoriatic":[25,492],"arthritis":[26],"presented":[27],"widespread":[29],"active":[30,190],"disease":[31,38,290,444,465,543],"despite":[32,314],"multiple":[33,63,533],"prior":[34,239,530,608],"systemic":[35,329],"therapies.":[36],"His":[37],"course":[39],"had":[40,131,204],"been":[41,611],"characterized":[42],"by":[43,363,639],"frequent":[44],"treatment":[45,397,629],"failures":[46],"or":[47,328,373],"secondary":[48,152],"loss":[49,153,249,352,401,451,469,568],"response.":[51,404],"Previous":[52],"therapies":[53],"included":[54,270],"acitretin,":[55],"ciclosporine,":[56],"apremilast,":[57],"narrowband":[58],"UVB":[59],"phototherapy,":[60],"methotrexate,":[61],"biologics:":[64],"adalimumab":[65],"40":[66],"mg":[67,76,83,90,97,104,111,119,146,173,184,262,273],"every":[68,175,263],"2":[69,114,377],"weeks":[70,177,265],"for":[71,78,85,92,99,106,113,121,126,311],"eight":[72],"months;":[73,80,87,94,101,108,115],"etanercept":[74],"50":[75],"weekly":[77,143],"5":[79],"infliximab":[81],"500":[82],"8-weekly":[84,112],"4":[86,127,142,471],"ustekinumab":[88],"90":[89],"12-weekly":[91],"7":[93,320],"secukinumab":[95],"300":[96],"4-weekly":[98,105,120],"8":[100],"ixekizumab":[102],"80":[103],"6":[107,323,527],"risankizumab":[109],"150":[110],"guselkumab":[117],"100":[118],"30":[122,251],"months":[123,140,277,313],"again":[125],"months.":[128,324,431],"The":[129,225],"patient":[130,282,346,424,437,540],"previously":[132],"achieved":[133,541],"his":[134,187,238],"best":[135],"clinical":[136,285,307,338,420,460],"response":[137,241,308,339,490,564,625],"11":[139],"dose":[144],"320":[145,261],"bimekizumab;":[147],"however,":[148,446],"he":[149,203],"developed":[150],"a":[151,257,315,345,485,554,595],"efficacy":[155,355,570,609],"following":[156,278,340],"generalized":[157],"sunburn,":[158],"subsequent":[160],"Koebnerization":[161],"suberythrodermic":[163],"flare":[164],"(Figure":[165],"1).":[166],"He":[167,296],"was":[168,228,266,309,433,565],"transitioned":[169],"to":[170,242,254,396,442,516,532,574,618,627],"tildrakizumab":[171],"200":[172],"subcutaneously":[174],"four":[176,264],"in":[178,344,409,416,435,491,524,588,598,632],"combination":[179,410],"oral":[181],"methotrexate":[182,271,414],"20":[183],"weekly,":[185],"but":[186],"remained":[189],"ongoing":[192],"flares":[193],"toward":[194],"the":[195,210,231,281,337,423,447,456,495,539,562,582,645,652],"end":[196],"each":[198],"dosing":[199],"interval.":[200],"On":[201],"examination,":[202],"extensive":[205,529],"erythematous,":[206],"scaly":[207],"plaques":[208],"involving":[209],"upper":[211],"lower":[213],"limbs":[214],"trunk,":[216],"relative":[218],"facial":[219],"sparing":[220],"associated":[222],"scalp":[223],"involvement.":[224],"PASI":[226],"19":[229],"at":[230],"11-month":[232],"review":[233],"after":[234],"commencing":[235],"tildrakizumab.":[236],"Given":[237],"favorable":[240],"bimekizumab,":[243],"limited":[244,606],"alternatives":[245],"recent":[247],"weight":[248,317,450,468,482,497],"kg":[252,321],"due":[253],"lifestyle":[255],"modifications,":[256],"retrial":[258,552,592],"bimekizumab":[260,279,343,408],"commenced.":[267],"Concomitant":[268],"therapy":[269,441],"7.5":[272],"weekly.":[274],"At":[275],"six":[276,430],"retreatment,":[280],"demonstrated":[283],"substantial":[284,449],"improvement":[286],"minimal":[288],"residual":[289],"(PASI":[291],"<":[292],"2;":[293],"Figure":[294],"2).":[295],"reported":[297],"improved":[298,457,464],"quality":[299],"life":[301],"reduced":[303],"symptom":[304],"burden.":[305],"This":[306,334,512,549],"maintained":[310],"12":[312],"gradual":[316],"gain":[318],"over":[322],"No":[325],"injection-site":[326],"reactions":[327],"adverse":[330],"effects":[331],"were":[332],"observed.":[333],"case":[335,513,580],"highlights":[336,550],"retreatment":[341,508,523],"treatment-resistant":[348],"psoriasis.":[350,590,634],"Secondary":[351],"biologic":[354,520,534,555,624],"is":[356,499],"well":[357],"recognized":[358],"may":[360,393,452,593],"be":[361],"mediated":[362],"immunogenicity":[364],"(such":[365],"as":[366,438,459,484,642],"development":[367],"antidrug":[369],"antibodies),":[370],"pharmacodynamic":[371],"tolerance,":[372],"external":[374,576],"inflammatory":[375,391],"triggers.1,":[376],"In":[378],"this":[379,436,579],"patient,":[380],"it":[381],"coincided":[382],"significant":[384],"sunburn":[385],"Koebnerization,":[387],"suggesting":[388],"that":[389,507,551],"acute":[390],"stress":[392],"have":[394,454,462],"contributed":[395],"failure":[398],"rather":[399,504],"than":[400,505],"drug":[403],"Importantly,":[405],"reintroduction":[406],"concomitant":[412],"low-dose":[413],"resulted":[415],"rapid":[417],"sustained":[419],"improvement,":[421],"achieving":[425],"nearly":[426],"clear":[427],"skin":[428],"within":[429],"Methotrexate":[432],"used":[434],"an":[439,500],"adjuvant":[440],"optimize":[443,628],"control;":[445],"patient's":[448,496],"also":[453,514],"influenced":[455],"response,":[458],"studies":[461,615],"shown":[463],"control":[466,544],"management.3,":[470],"Although":[472],"these":[473],"findings":[474],"involve":[475],"different":[476],"agents":[477],"populations,":[479],"they":[480],"support":[481],"reduction":[483],"potential":[486,502],"modifier":[487],"therapeutic":[489,586],"disease.":[493],"Accordingly,":[494],"change":[498],"important":[501],"confounder":[503],"proof":[506],"alone":[509],"restored":[510],"efficacy.":[511],"adds":[515],"evidence":[517],"supporting":[518],"sequential":[519],"switching":[521],"psoriasis.5,":[526],"Despite":[528],"exposure":[531],"classes":[535],"small-molecule":[537],"therapies,":[538],"meaningful":[542],"without":[545],"cumulative":[546],"safety":[547],"concerns.":[548],"can":[556],"remain":[557],"clinically":[558],"effective,":[559],"particularly":[560,601],"when":[561,602],"previous":[563],"robust":[566],"appears":[571],"temporally":[572],"linked":[573],"modifiable":[575],"factors.":[577],"Overall,":[578],"underscores":[581],"importance":[583],"individualized":[585],"strategies":[587,631],"refractory":[589],"Biologic":[591],"represent":[594],"valuable":[596],"option":[597],"selected":[599],"patients,":[600],"alternative":[603],"treatments":[604],"are":[605,616],"has":[610],"demonstrated.":[612],"Further":[613],"prospective":[614],"warranted":[617],"better":[619],"define":[620],"predictors":[621],"successful":[623],"sequencing":[630],"recalcitrant":[633],"Open":[635],"access":[636],"publishing":[637],"facilitated":[638],"Monash":[640,648],"University,":[641],"part":[643],"Wiley":[646],"-":[647],"University":[649,656],"agreement":[650],"via":[651],"Council":[653],"Australasian":[655],"Librarians.":[657],"None.":[658]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2026-11-05T00:00:00"}